Tumor Ablation Market Worth $1.4 Billion

Tumor Ablation Market Report by MarketandMarkets

Technological advancement, new product developments in cryoablation, and the rising incidence of cancer are the major indicators contributing to the growth of the market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142550258

Browse in-depth TOC on “Tumor Ablation Market”

146 – Tables
56 – Figures
192 – Pages

Tumor Ablation Market Scope:

Report Coverage

Details

Market Revenue in 2024

$0.8 billion

Estimated Value by 2029

$1.4 billion

Growth Rate

Poised to grow at a CAGR of 10.0%

Market Size Available for

2022–2029

Forecast Period

2024–2029

Forecast Units

Value (USD Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Technology, Product type, mode of treatment, application, end user, and region

Geographies Covered

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Rising healthcare expenditure across emerging economies

Key Market Drivers

Increasing cancer incidence and rising geriatric population

Microwave ablation segment to register significant growth rate over the forecast period of 2024-2029.

Based on the technology, the global market is further segmented into microwave, radiofrequency, high-intensity focused ultrasound, cryoablation, and other technologies. The microwave ablation segment is anticipated to register the highest growth rate over in the near future owing to the promising results of the treatment. This is attributed to the increasing focus on microwave ablation due to its notable benefits such as speed, improved success rate and precise ablation. High efficiency rate of microwave ablation for various cancers is expected to increase its utilization in the end user facilities in coming years.

The generators segment will register a significant growth rate over the forecast period of 2024-2029.

The global tumor ablation market is segmented by product type into generators and probes/electrodes. Major shares of the segment are attributed to the rising patient population and rising adoption of ablation treatment globally. Increasing cancer population due to change in lifestyle, rising obesity, and increasing alcohol consumption contributes to the rise in the number of ablation procedures at hospitals and clinics. The rise in the number of procedures performed will ultimately support the growth of generators segment and is expected to register the significant growth during the forecast period.

Percutaneous ablation segment to register a significant growth rate over the forecast period of 2024-2029.

In terms of mode, global tumor ablation market is divided by mode of treatment into surgical, percutaneous, and laparoscopic ablation. In 2023, the surgical ablation segment held the major share of the market.  Increasing healthcare expenditure and cancer awareness campaigns support the growth of this segment. Educating people through various campaigns for the importance of early detection has been responsible for rise in the number of cancer screening in end user facilities. This ultimately supports the increasing number of ablation procedures and contributes to the exponential growth of the segment.

Liver cancer segment is in application to register a significant growth over the forecast period of 2024-2029.

By application, the global tumor ablation market is segmented by application into liver cancer, lung cancer, kidney cancer, bone cancer, and other applications. The growing trend towards ablation technology over traditional treatments and rising public awareness drive this segment’s growth. Consistent rise in the global cases of hepatocellular carcinoma, clinical studies showing improved success rate, and rising proportion of older age population have supported the growth of liver cancer segment in tumor ablation market.

The hospitals and clinics accounted for the major share of tumor ablation market by end user in 2023.

Based on end users, the tumor ablation market is segmented into hospitals & clinics, cancer care centers, and other end users. The major share of the end-user segment was held by hospitals and clinics in 2023. The increasing prevalence of liver cancer, advancements in tumor ablation technology, and a growing emphasis on non-invasive treatment options contribute to the expanding utilization of ablation treatment within healthcare settings for comprehensive patient care.

The Asia Pacific market will register significant growth in the market during the forecast period.

The Asia Pacific tumor ablation market is estimated to register significant growth from 2024 to 2029. The increasing target patient population, favorable reimbursement scenario, and growing disposable income fuel the APAC region’s market growth. Moreover, the APAC region has experienced a rise in investments by governments and major players, offering significant growth opportunities for the key players.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=142550258

Tumor Ablation Market Dynamics:

Drivers:

  1. Increasing cancer incidence and rising geriatric population

Restraints:

  1. Increasing cancer incidence and rising geriatric population

Opportunities:

  1. Rising healthcare expenditure across emerging economies

Challenge:

  1. Rising adoption of refurbished tumor ablation systems

Key Market Players of Tumor Ablation Industry:

As of 2023, prominent players in the tumor ablation market are Medtronic Plc (Ireland), Johnson & Johnson MedTech (US), and Stryker Corporation (US).

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1–30%, Tier 2–42%, and Tier 3– 28%
  • By Designation: Director-level–10%, C-level–14%, and Others–76%
  • By Region: North America–40%, Europe–30%, Asia Pacific–22%, Latin America–6%, and the Middle East & Africa–2%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=142550258

Tumor Ablation Market – Key Benefits of Buying the Report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall tumor ablation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:

  • Analysis of key drivers (increasing cancer incidence and rising geriatric population, rising focus on minimally invasive procedures, technological advancements in the field of tumor ablation, rising number of awareness campaigns and early detection), restraints (high cost of tumor ablation systems, unfavorable reimbursement scenario), opportunities (rising healthcare expenditure across emerging countries, increasing number of hospitals), and challenges (rising adoption of refurbished tumor ablation systems, hospital budget cuts) influencing the growth of the tumor ablation market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the tumor ablation market
  • Market Development: Comprehensive information about lucrative markets–the report analyses the tumor ablation market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tumor ablation market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players – such as Johnson & Johnson (US), Medtronic Plc (Ireland), Stryker Corporation (US), Varian Medical Systems, Inc. (US), Olympus (Japan), AngioDynamics, Inc. (US), Boston Scientific Corporation (US) among others.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.